[
 {
  "title": "Clinical Treatment and Medical Evidence",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Discusses the differences in clinical treatment from the existing medical evidence, often leading to useless, or even harmful, outcomes for patients.",
  "content_length": 149,
  "content_tokens": 26,
  "embedding": []
 },
 {
  "title": "Structural Problems in Oncology",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Takes a deep dive into the field’s structural problems, which include the disconnect between progress and funding, drug costs, and financial conflicts of interest.",
  "content_length": 163,
  "content_tokens": 32,
  "embedding": []
 },
 {
  "title": "Six Hallmarks of Successful Cancer Policy",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Concludes with his “six hallmarks of successful cancer policy” as a potential roadmap to sustained progress against cancer and a way to avoid repeating the policy and practice mistakes of the past.",
  "content_length": 197,
  "content_tokens": 39,
  "embedding": []
 },
 {
  "title": "Structural Problems in Oncology",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Structural problems in oncology include: Huge costs for small improvements, medical reversal—when medical practices are adopted based on low levels of evidence, slow progress in cancer research (despite all the hype and propaganda), the burden of payment is not matched with those making treatment decisions.",
  "content_length": 308,
  "content_tokens": 56,
  "embedding": []
 },
 {
  "title": "Six Hallmarks of Successful Cancer Policy",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The six hallmarks of successful cancer policy include: Independence, Evidence, Relevance, Affordability, Possibility, Agenda.",
  "content_length": 125,
  "content_tokens": 27,
  "embedding": []
 },
 {
  "title": "Tumor Genome Sequencing and Liquid Biopsies",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Discussion on tumor genome sequencing and liquid biopsies.",
  "content_length": 58,
  "content_tokens": 11,
  "embedding": []
 },
 {
  "title": "Clinical Philosophy",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Discussion on clinical philosophy, being skeptical without being too contrarian, and practicing medicine without perfect information.",
  "content_length": 133,
  "content_tokens": 20,
  "embedding": []
 },
 {
  "title": "Optimizing Brain Health",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Alzheimer's disease including the possibility of a vascular hypothesis as well as the factors that can impact disease risk such as type 2 diabetes, blood pressure, omega supplementation, exercise, sauna, and more. The breakdown of the blood-brain barrier in neurodegenerative disease. An explanation for the observation that type 2 diabetes increases risk of Alzheimer's disease. The role of omega-3 fatty acids (EPA and DHA) in brain health and prevention of neurodegeneration. Blood pressure: an important modifiable lifestyle factor that can affect Alzheimer's disease risk. Possible mechanisms by which exercise reduces the risk of Alzheimer's disease. Possible brain benefits of sauna. The relationship between cardiorespiratory fitness and dementia risk. How exercise may reduce the risk of cancer. Impact of alcohol consumption on breast cancer risk and overall health. Exercise as an intervention for poor sleep habits. The longevity benefits of consuming adequate protein and strength training to preserve muscle mass and strength. How to get enough of the right kind of protein in your diet. Fasting: weighing the risk vs. reward.",
  "content_length": 1140,
  "content_tokens": 219,
  "embedding": []
 },
 {
  "title": "Preventing Cardiovascular Disease",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The latest in diagnostic imaging, blood pressure, metabolic health, and more.",
  "content_length": 77,
  "content_tokens": 15,
  "embedding": []
 },
 {
  "title": "Weight Loss Drugs and Geroprotective Agents",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent.",
  "content_length": 81,
  "content_tokens": 23,
  "embedding": []
 },
 {
  "title": "Cell and Gene Therapy",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The history of the cell, cell therapy, gene therapy, and more.",
  "content_length": 62,
  "content_tokens": 15,
  "embedding": []
 },
 {
  "title": "Medical Reversal",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "There were things we were doing that were not supported by strong evidence, there were some things that appeared to run counter to the best evidence. It didn’t make a lot of sense to me. This realization began his foray into medical research. He started doing studies on ineffective practices that had become part of medical culture, termed “medical reversal,” and has published papers about it.",
  "content_length": 395,
  "content_tokens": 80,
  "embedding": []
 },
 {
  "title": "Stents for Chronic Stable Angina",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "A stent is a transformative, life-saving intervention in a critical situation, such as an AST elevation-related myocardial infarction, a total blockage of the artery. Stents became very popular for chronic stable angina. However, a large, mega randomized control trial called Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) found that for people with chronic stable angina, there was no improvement in survival and no reduction in subsequent myocardial infarction. Stents have complications: cardiac arrest occlusion of the stent, a thrombus that forms within this foreign body.",
  "content_length": 617,
  "content_tokens": 133,
  "embedding": []
 },
 {
  "title": "Placebo Effect in Medical Interventions",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "One theme in medical reversal is 'mechanical interventions done to alleviate a subjective symptom' like angina or pain or dyspnea—Studies suggest this is a placebo effect, no better than a sham intervention. For example, with degenerative osteoarthritis of the knee, can do surgery to debride the cartilage, which might get better results than PT or taking ibuprofen. But if you just put scope in but not actually do anything, patients still report feeling better.",
  "content_length": 464,
  "content_tokens": 101,
  "embedding": []
 },
 {
  "title": "Challenges in Oncology",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Oncology is challenging because what we call 'cancer' is really very dissimilar diseases. There is variation even within cancer types. For example, non-small cell lung cancer, which itself is a category of lung cancer, can be further divided into categories like EGFR mutation type, ALK rearrangement type, RET, and ROS1. We have all these molecular categories, we have RAS, this undruggable target. We have superimposed that with the role of immunotherapy.",
  "content_length": 457,
  "content_tokens": 102,
  "embedding": []
 },
 {
  "title": "Structural Problems in Oncology",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "In 71 consecutively approved drugs for solid cancers, as a famous study showed, the average improvement was 2.1 months. And the cost of those meds is 100,000 to $200,000 per year of treatment, need to take it for 8-10 months to get the two-month benefit. Another problem is medical reversal—when medical practices are adopted based on low levels of evidence. This led to the book Ending Medical Reversal.",
  "content_length": 404,
  "content_tokens": 92,
  "embedding": []
 },
 {
  "title": "Health Risks and Misconceptions",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The WHI is arguably the worst study that’s ever been done. The biggest WHI headline was that HRT increased breast cancer, which later turned out not to be a correct conclusion. It also raised questions about the difference between relative risk and absolute risk.",
  "content_length": 263,
  "content_tokens": 54,
  "embedding": []
 },
 {
  "title": "Three Broad Pillars of Disease",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "There are three broad pillars of disease: 1) cardiovascular and cerebrovascular disease, 2) cancer, and 3) neurodegenerative disease. The foundation of metabolic disease (hyperinsulinemia, insulin resistance, fatty liver disease, type 2 diabetes) makes these three disease processes get a lot worse.",
  "content_length": 299,
  "content_tokens": 64,
  "embedding": []
 },
 {
  "title": "Progress in Cancer Research",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Hundreds of billions of dollars have been invested in cancer research. We’ve made great progress on a few diseases like chronic myeloid leukemia (CML), but the average patient still has a very grave prognosis. A drug that increased survival for about 20 days costs $38,000 for the extra days.",
  "content_length": 292,
  "content_tokens": 64,
  "embedding": []
 },
 {
  "title": "The Burden of Payment in Oncology",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The burden of payment is not matched with those making treatment decisions. Bevacizumab (Avastin) was the first such drug approved (for colon cancer) and costs about $100K for a year. Some countries wouldn’t pay for it because it didn’t meet their payment threshold guidelines.",
  "content_length": 277,
  "content_tokens": 66,
  "embedding": []
 },
 {
  "title": "No-brainer Moves in Oncology",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The no regret moves in oncology today are: 1) surgery to remove localized cancers, 2) radiotherapy, and 3) drugs. The no-brainers are when there’s some benefit and the toxicity is low or when there’s a benefit but the toxicity is reversible.",
  "content_length": 241,
  "content_tokens": 61,
  "embedding": []
 },
 {
  "title": "Fool’s Gold Treatments in Oncology",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Some treatments are much more dubious and have caustic, toxic treatments with long-term toxicity. Patients are in a very difficult position – they don’t know all the science or how to think about the data. Decision-making is a thorny process; sometimes there is pressure to make certain decisions from family members.",
  "content_length": 317,
  "content_tokens": 66,
  "embedding": []
 },
 {
  "title": "Progression-free Survival in Cancer Studies",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Progression-free survival is often interpreted as the time it takes for cancer to get worse. It is the time from when a patient enrolls on a study to one of four things happening: death, a new lesion on a CAT scan, tumor gets 20% bigger, or tumor gets smaller, then bigger. Measuring on a CAT scan is not like measuring your height – it’s much less precise and doctors don’t always agree about where the tumor ends and where the normal tissue begins.",
  "content_length": 450,
  "content_tokens": 104,
  "embedding": []
 },
 {
  "title": "The Six Hallmarks of Cancer",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The Six Hallmarks of Cancer were proposed by Hanahan and Weinberg in one of the most cited papers in oncology. It includes the biological hallmarks such as invasion of the basement membrane, poor immune surveillance, angiogenesis, etc.",
  "content_length": 235,
  "content_tokens": 50,
  "embedding": []
 },
 {
  "title": "Cancer Policy Hallmark: Independence",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "This hallmark is about conflicts of interest. Industry ties to those who should be watching: it funds patient advocacy groups, rotating door with industry and FDA, most expert oncologists get drug funding and sometimes support questionable drugs. Guidelines are written by people making large amounts of money from industry. The solution is not to set hard rules with punishments, because that doesn’t change behavior. Instead create a different set of incentives.",
  "content_length": 464,
  "content_tokens": 85,
  "embedding": []
 },
 {
  "title": "Cancer Policy Hallmark: Evidence",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "When we give cancer drugs, we care about two things: increased survival or health related quality of life. In our current system, one third of approved drugs shrink tumors more than 30% in a fraction of people, one third delay tumor growth by 20%, and one third allow you to live longer and/or better.",
  "content_length": 301,
  "content_tokens": 64,
  "embedding": []
 },
 {
  "title": "Cancer Policy Hallmark: Relevance",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Need more studies done on subjects who are more representative of average Americans. Need to study average people to see if the drugs work as they will be prescribed. Will reduce drug success rates due to both decreased tolerability and actual poor response.",
  "content_length": 258,
  "content_tokens": 47,
  "embedding": []
 },
 {
  "title": "Cancer Policy Hallmark: Affordability",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Affordability is a thorny problem. If a drug is approved in the US, Medicare has to pay for it and can’t negotiate the price. We should give Medicare the ability to decline to pay for drugs. Many drugs, for the most part, are out of reach of billions and billions of people. About 50% of pharmaceutical spending in the world comes from the US even though we account for maybe 4% of the world’s population.",
  "content_length": 405,
  "content_tokens": 94,
  "embedding": []
 },
 {
  "title": "Drug Side Effects and Costs",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "A drug “lowers the rate of a blood protein” but also causes ocular impairment in almost everyone who takes it, in some cases severe. We don’t know if it makes better live longer or better, but ophthalmology costs are high.",
  "content_length": 222,
  "content_tokens": 55,
  "embedding": []
 },
 {
  "title": "Value Based Pricing Model for Drugs",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Value based pricing model:  we should pay more for drugs that provide us more value with more incremental survival benefits. With any policy, you will get unintended consequences and people finding unforeseeable paths of least resistance.",
  "content_length": 238,
  "content_tokens": 44,
  "embedding": []
 },
 {
  "title": "Insurance Companies and Drug Prices",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "CMS might be 25-35% of insurance in the US, but why haven’t private insurance companies banded together to negotiate prices? There have been many news reports about patients’ personal battles with health insurance companies’ drug coverage denials over the last 30 years.",
  "content_length": 270,
  "content_tokens": 58,
  "embedding": []
 },
 {
  "title": "Affordable Care Act and Insurance Company Profit",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Affordable Care Act  capped insurance company profit on revenue to 20% profit on revenue (minimum medical loss ratio or MLR). If can’t earn more than 20%, have high incentive to make as much as possible.",
  "content_length": 203,
  "content_tokens": 48,
  "embedding": []
 },
 {
  "title": "Insurers and Pre-Authorization Requests",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Why do insurers impose pre-authorization requests and other requirements that make things difficult for doctors? One, the insurer’s incentive is to make sure year-to-year variability of costs is predictable and that they can model that out and make sure their premiums go where they need them to go to ensure their profit revenues.",
  "content_length": 331,
  "content_tokens": 66,
  "embedding": []
 },
 {
  "title": "Role of National Institutes of Health in Drug Development",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "We talk about fledgling biotech, the pharmaceutical industry, etc. but forget the role of the National Institutes of Health (NIH)  in drug development. NIH bears some of the risk, funds some “science for science’s sake,” identifying targets that are then clinically exploited. We spend about $30B a year on NIH, but that’s not nearly enough.",
  "content_length": 341,
  "content_tokens": 80,
  "embedding": []
 },
 {
  "title": "Increasing Science Funding",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "We should increase science funding slowly and steadily (if increase it too fast, not used yet used it and will result in waste). Must separate science from politics – funding should be stable and not dependent on elections.",
  "content_length": 223,
  "content_tokens": 42,
  "embedding": []
 },
 {
  "title": "Distribution of Research Funding",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "We give out billions of dollars in research funding but have never really studied how it should be distributed. Some labs are flush with money while others get almost none. We need to do some studies on measures of equity of who gets the money, the research satisfaction, burnout, measures of how translation occurs, etc.",
  "content_length": 321,
  "content_tokens": 63,
  "embedding": []
 },
 {
  "title": "Tumor Genome Sequencing and Liquid Biopsies",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Is there a role in oncology for tumor genome sequencing? Next generation sequencing (NGS) and  tumor genomics: some cancer patients need to be tested for mutations. There are maybe 20 or 30 mutations a good oncologist should know. Liquid biopsies are done for leukemia. What about the phase two data on liquid biopsies for solid organ tumors and lymphomas?",
  "content_length": 356,
  "content_tokens": 79,
  "embedding": []
 },
 {
  "title": "Practicing Medicine Without Perfect Information",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Example when Vinay took a different stance and others gave him a hard time: the use of dexamethasone for COVID. During COVID, docs were trying everything and doing whatever they could think of for COVID patients. The best way to keep a balance between skepticism blind acceptance is to go into the clinic, where patients are taking drugs you might be skeptical of.",
  "content_length": 364,
  "content_tokens": 77,
  "embedding": []
 },
 {
  "title": "Patient Decision-Making Process",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Then walk the patient through the decision-making process so they understand if it’s worth it to them to take the risks. Different people will choose differently.",
  "content_length": 162,
  "content_tokens": 33,
  "embedding": []
 },
 {
  "title": "Art of Medicine",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The more you practice medicine, the more you realize that it’s an art. You’re never going to have perfect information. You’re going to have to make decisions today with less than perfect information.",
  "content_length": 199,
  "content_tokens": 46,
  "embedding": []
 },
 {
  "title": "Cost of Skepticism and Blind Acceptance",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "If you’re too much of a skeptic, there’s a cost of doing nothing. If you blindly accept everything, you are almost unquestionably subjecting patients to unnecessary treatments.",
  "content_length": 176,
  "content_tokens": 40,
  "embedding": []
 },
 {
  "title": "Importance of Decision Making in Medicine",
  "date": "October 19, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Peter and his colleagues debate with each other, but we never lose sight of the fact that it’s not an intellectual pursuit. At the end, a decision needs to be made. Recognizing that sometimes others might do things differently than we would helps balance skepticism.",
  "content_length": 266,
  "content_tokens": 54,
  "embedding": []
 }
]